Previous investigations have revealed the crucial role of inflammatory cells (T lymphocytes, B cells, monocytes, macrophages) and pro-inflammatory cytokines winterleukin 1b (IL-1b), IL-6, tumour necrosis factor-a (TNFa), interferon-c, IL-1ax in the pathogenesis of rheumatoid arthritis (RA) w1-3x. The rationale for blockade of TNFa was based upon several reports that demonstrated the particular importance of TNFa: high concentrations of TNFa were observed in synovial fluid, synoviocytes and synovial macrophages of patients with RA w4, 5x. Injection of TNFa in animals resulted in synovitis with infiltration of lymphocytes, monocytes and neutrophils in the articular cavity w6x. In addition, a relationship between synovial TNFa expression and disease activity in RA patients was observed w7x. In collagen-induced arthritis in mice, treatment with monoclonal antibodies to TNFa was able to diminish the production of IL-1 and granulocyte-macrophage colony-stimulating factor (GM-CSF) by synovial cells in vitro and to ameliorate synovitis and joint destruction w8-10x. These findings led to the conclusion that TNFa is an important therapeutic target in rheumatoid arthritis: in recent, placebocontrolled, double-blind, randomized studies, antiTNFa therapy proved to be very effective in improving clinical and laboratory disease activity and reducing inflammatory parameters w11-18x.
To further investigate the possible mechanisms responsible for the clinical efficacy of anti-TNFa therapy, we studied the short-term (24 h) and longterm (6 months) effects of anti-TNFa therapy on in vitro intracellular cytokine production in T lymphocytes and monocytes.
Methods and patients

Study population
Fifteen patients with active rheumatoid arthritis (RA), fulfilling the diagnostic criteria of the American College of Rheumatology for the classification of rheumatoid arthritis w19x, were evaluated before, after 24 h and after 6 months (just before administering the sixth infusion) of therapy with monoclonal chimeric anti-TNFa antibodies (3 mgukg i.v. at week 0, week 2, week 6, week 14, week 22, week 30) in combination with stable doses of methotrexate (12.5-20 mguweek i.m.) and stable low-dose corticosteroids (5-10 mguday) or non-steroidal anti-inflammatory drugs (NSAIDs) ( Table 1 ). The disease duration of the RA patients was 47 (23-279) months wmedian (range)x. Active disease was considered if the following criteria were present: morning stiffness lasting for more than 20 min, presence of at least six painful joints and four swollen joints and an erythrocyte sedimentation rate (ESR) of more than 28 mmuh or a C-reactive protein (CRP) of at least 1 mgudl. The clinical response at month 6 was performed by a blinded assessor and defined according to the American College of Rheumatology definitions of ACR 20, ACR 50 and ACR 70 w20x. A placebo-controlled, double-blind study was ethically not acceptable since the efficacy of anti-TNFa therapy is already well established in placebo-controlled, double-blind studies w11, 14x. All patients gave informed consent for the study.
Analysis of lymphocyte subsets
An aliquot of 100 ml of peripheral blood was incubated for 15 min in the dark at 48C with 10 ml of multi-colour monoclonal antibody panels (CD3-PerCP+CD4-FITC+CD8-PE; CD45-PerCP+CD3-FITC+CD19-PE; BD Biosciences, Erembodegem, Belgium). Subsequently, the remaining red blood cells were lysed with Facslysis (BD Biosciences) for 10 min at room temperature. Cells were fixed and pelleted at 400 g for 10 min. Afterwards, the cells were resuspended in phosphate-buffered saline (PBS) and analysed by FACScan flow cytometry (BD) within 24 h.
Intracellular cytokine analysis in lymphocytes
Cytokine-producing T lymphocytes were determined as previously described w21x. Briefly, peripheral whole blood cultures were incubated for 6 h at 378C and 5% CO 2 humidified atmosphere in the presence of 50 nguml phorbol-12-mirystate-13-acetate (PMA, Sigma, St Louis, MO, USA), 1 muml ionomycin (Sigma) and 1 mguml brefeldin A (Sigma) or brefeldin A alone. After stimulation, 100 ml of cells were stained with CD8-FITC (BD) and CD3-PerCP (BD). Cells were lysed with FacsLysis (BD) and permeabilized in 0.3% saponin in PBS. Cells were stained for 30 min with monoclonal anticytokine antibodies labelled with phycoerythrin (PE) (anti-Hu IL-2-PE, anti-Hu IL-4-PE, anti-interferon-PE; BD). Twenty thousand cells were measured on a FACScan (BD) flow cytometer and analysed with WinMDI 2.8 software. Analysis gates were set on lymphocytes according to forward and sideward scatter properties. CD4+ T lymphocytes were defined and gated out as CD3+CD8-and CD8+ T cells as CD3+CD8+ using a compensated fluorescence plot. Within this gate, intracellular cytokine-producing cells were determined in histogram mode (PE emission). Markers were set on the 99th percentile using isotype-matched irrelevant antibodies (mouse IgG1 RPE, Serotec Ltd, Oxford, UK) as a reference. Results were expressed as the percentage of cytokine-producing cells. T helper (T H2 uT H1 ) and T cytotoxic (T C2 uT C1 ) ratios were calculated in the following manner: values for IL-4 (representing a T H2 uT C2 cytokine) were divided by values for interferon-c or IL-2 (representing a T H1 uT C1 cytokine)-positive CD4+ or CD8+ T lymphocytes.
Intracellular cytokine analysis in monocytes
Intracellular cytokine production by monocytes was determined as previously described w22x. Cytokine content in monocytes was measured directly after blood sampling (basal level), after 8 h of culture (spontaneous production) and after 8 h of stimulation with lipopolysaccharides (LPS-stimulated production). Peripheral blood cultures were stimulated for 8 h with 1 mguml lipopolysaccharide Escherichia coli (LPS, Serotype 026:B6, Sigma) and 1 mguml brefeldin A (LPS-stimulated 
Statistics
Differences in numbers of T-cell subsets and cytokine production before and after therapy were calculated with Friedman's test and Wilcoxon's rank test. Correlations were assessed with Spearman's rank correlation test.
Results
Disease activity
After 6 months, 14 patients showed reduced symptoms and signs of RA (Table 2) , as judged by ACR 20 (20% of improvement); nine of 15 patients achieved ACR 50.
White blood cell counts
Therapy with anti-TNFa resulted in an increase in lymphocyte counts in the peripheral blood, 24 h after the first infusion (Table 3 ). The elevation of lymphocyte numbers was mainly due to an absolute increase of CD3+ T cells (P=0.0001) ( Table 3 ). The absolute number of CD4+ T cells increased drastically after 24 h (P=0.0003), with no differences after 6 months (Table 3) . Similarly, the number of CD8+ T cells increased after 24 h (P=0.0006). There was no change in numbers of peripheral blood B lymphocytes (CD19+). In addition, a rapid decrease of absolute numbers of monocytes (CD14+) was found (P=0.01) ( Table 3) . Results are expressed as median (range) percentages and as absolute numbers. *P < 0.05 compared with d0.
Anti
Lymphocytic cytokines
Twenty-four hours after treatment with anti-TNFa, the percentages and absolute numbers of IL-4, interferon-c and IL-2-positive CD4+ T cells were significantly increased (P=0.05, P=0.004, P=0.03, respectively) ( Table 4 ). The rise in IL-4-positive CD4+ T cells was more pronounced than the rise in interferon-c and IL-2-positive CD4+ T cells, resulting in a significant increase of the T H2 uT H1 cytokine ratio in the peripheral blood (for IL-4uIL-2 P=0.0006 and for IL-4uinterferon-c P=0.0007, respectively) ( Fig. 1) . After 6 months, there was still an augmented T H2 uT H1 cytokine ratio (for IL-4uIL-2 P=0.01 and for IL-4uinterferon-c P=0.003, respectively) ( Fig. 1) . For CD8+ T cells, the percentages and absolute numbers of interferon-c-, IL-2-and IL-4-positive cells were also higher after 24 h (P=0.0001, P=0.01) ( Table 4 ). In contrast, the absolute numbers of both interferon-c-, IL-2-and IL-4-positive CD8+ T cells did not alter after 6 months of therapy, compared with baseline values (Table 4 ). The T C2 uT C1 cytokine ratio, represented by IL-4uIL-2 and IL-4uinterferon-c, did not change for CD8+ T cells.
Monocytic cytokines
Basal levels and spontaneous production (after 8 h of culture) of IL-1b, IL-6 and TNFa were significantly decreased 24 h after the first administration of antiTNFa and after 6 months of therapy (P < 0.05) (Fig. 2) . Stimulated production (after 8 h of culture with LPS) of IL-1b, IL-6 and TNFa showed a similar rapid decline after 24 h and 6 months of treatment (P < 0.05) (Fig. 2) .
Basal IL-12 levels were significantly decreased after 24 h and after 6 months, compared with baseline: 1240 
Discussion
It has been shown that therapy with chimeric monoclonal TNFa antibodies leads to a rapid improvement of clinical and biological signs of inflammation in RA w11-14x. There is considerable evidence for two major mechanisms of action: first, there is a reduced cell influx of inflammatory cells into the joints, due to downregulation of the synovial endothelial adhesiveness and the chemotactic gradient w24-27x; second, there is an inhibition of the pro-inflammatory cytokine cascade. It seems that inflammation in RA, characterized by initial TNFa production, which subsequently enhances the production of other pro-inflammatory cytokines such as IL-1, IL-6, IL-8, IL-12 and GM-CSF, can be inhibited by blocking TNFa w26-31x.
To our knowledge, this is the first study that investigated the influence of both the short-term (24 h) and long-term (6 months) effect of anti-TNFa therapy on intracellular cytokine profiles in T lymphocytes and monocytes. In contrast, previous studies only evaluated the cytokine profile after a single infusion of antiTNFa w29-33x. In the present study, we observed a clear reduction of capacity to produce IL-1b, IL-6, Results are expressed as median (range) percentage cytokine-positive T lymphocytes and as absolute numbers of cytokine-positive T lymphocytes.
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TNFa and IL-12 in monocytes, immediately after the first infusion of anti-TNFa therapy, which persisted after 6 months of therapy. A flow cytometric intracellular technique was applied in this study to evaluate the altered capacity of monocytes to produce pro-inflammatory cytokines. By blocking produced cytokines intracellularly in the Golgi apparatus, we could avoid complexation of cytokines with their inhibitors, which could be an explanation for some discrepancies in other studies, detecting cytokines in serum with ELISAs: Oshima et al. w31x detected no substantial serum IL-1b, Lorenz et al. w30x observed a decrease in IL-1b production, whereas Charles et al. w32x found no difference in serum IL-1b levels after a single infusion with anti-TNFa antibodies. Our findings regarding IL-6 production on a shortand longer-term basis are completely in line with previous data that reported decreased serum IL-6 production w29-32x. The decrease in IL-6 could explain the rapid and sustained decrease in acute-phase CRP, also observed in other trials with anti-TNFa therapy w11, 16-18, 32x .
On the basis of in vitro experiments, which showed that IL-12 production in RA was partly inhibited by anti-TNFa w34x, it was expected that TNFa neutralization would lead to down-regulation of IL-12 production, which was observed in our study.
By serum studies using ELISA assays, not distinguishing immunoreactive from bioactive cytokines, it has not been possible to test equivocally the prediction that TNF blockade will inhibit TNFa production in vivo w31, 32x. In our study, basal, spontaneous and LPS-stimulated TNFa production significantly decreased after 24 h and after 6 months of therapy. In accordance with our findings in peripheral blood monocytes, analysis of synovial tissue before and after treatment showed that TNF blockade was able to reduce TNFa synthesis in the joints w28x.
Taken together, this study provides evidence that antiTNFa blockade can deactivate the pro-inflammatory cytokine cascade, as demonstrated by reductions in serum CRP, IL-1, IL-6, TNFa and IL-12 production.
In addition to the decreased capacity of monocytes to produce pro-inflammatory cytokines, a decrease in absolute monocyte counts was observed, which has been described previously w25, 29-31x. One of the underlying mechanisms could be complement lysis of membraneous TNFa-expressing monocytes that bind the anti-TNFa antibody w35x; an alternative explanation would be antibody-dependent cellular cytotoxicity of membraneous TNFa-expressing monocytes w35x. Recently, a third mechanism for the decrease in monocyte counts is reported: the capacity of anti-TNFa antibodies to induce apoptosis of monocytes in patients with Crohn's disease w36x.
In addition, we demonstrated an increased capacity of monocytes to produce IL-10, which is in accordance with previous findings of increased serum levels of IL-10 after one infusion of anti-TNFa therapy w31x.
This up-regulated IL-10 production can contribute to the correction of the disequilibrium between pro-and anti-inflammatory cytokines in monocytes of RA patients. In vitro experiments reported enhanced proinflammatory cytokine (IL-1, IL-6, IL-8, TNFa, GM-CSF) production by blocking IL-10 or a reduction by addition of exogenous IL-10 w37x, demonstrating an important role for IL-10 as an anti-inflammatory and immunoregulatory cytokine in monocytes.
In our study, an increased absolute number of lymphocytes was observed: several reports describe an increase of peripheral blood T H1 cells in patients treated with anti-TNFa, associated with the down-regulation of adhesion molecules in the synovium w25, 26, 31, 33x, which could be an important factor for inhibiting T H1 cells from migrating into the synovium and inhibiting the release of their T H1 cytokines in the synovium.
We investigated whether TNFa therapy alters the amount of type 1 (represented by IL-2 and interferon-c) and type 2 (represented by IL-4) CD4+ and CD8+ T lymphocytes within the peripheral blood of RA patients. We could confirm the data presented by Maurice et al. w33x and Lorenz et al. w29x, who showed a rise for IL-4-, IL-2-and interferon-c-positive CD4+ T cells shortly after a single infusion. Moreover, we demonstrated that the increased number of IL-4-, interferon-c-and IL-2-positive CD4+ T cells was still present after 6 months of anti-TNFa therapy. This increase of T H1 and T H2 cytokine production, at the same time as the upregulation of IL-10 production and down-regulation of IL-12, is a very interesting and unexpected finding since IL-10 was originally discovered as a T H1 -inhibiting cytokine w38-40x, whereas IL-12 is known to play an important role in the development of a T H1 response and subsequent interferon-c production in RA w41x.
According to Cope et al. w42x, increased IL-2, IL-10 and interferon-c production in T lymphocytes and improved proliferative responses were reported to occur after prolonged in vitro and in vivo TNFa blockade. Further investigation of patients will allow us to define how TNFa therapy enhances T-cell responsiveness and type 1utype 2 cytokine production. The ratio of T H2 uT H1 was increased in comparison with baseline in our study, suggesting a normalization of the initial T H1 cytokine predominance in RA patients towards a more pronounced anti-inflammatory T H2 cytokine balance, in contrast to the study of Maurice. This discrepancy may be partially due to methodological differences (optimal incubation and use of brefeldin A or monensin to block cytokine secretion) w22, 43-46x.
In conclusion, repeated administration of anti-TNFa therapy might down-regulate the monocytic capacity to produce pro-inflammatory cytokines and induce a shift to a more pronounced anti-inflammatory T H2 cytokine balance. Further investigation on cytokine profiles in dose-response studies with anti-TNFa therapy has to be performed in order to elucidate the complex mechanisms of anti-TNFa therapy, responsible for the clinical efficacy in rheumatoid arthritis. 
